[February 26, 2015]

Research and Markets: Obsessive-Compulsive Disorder Therapeutics Pipeline Review, H1 2015 - 9 Companies & 14 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/8qlfqw/obsessivecompulsi) has announced the addition of the "Obsessive-Compulsive Disorder - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Obsessive-Compulsive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development fr Obsessive-Compulsive Disorder and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• AbbVie Inc.
• Addex Therapeutics Ltd
• C4X Discovery Ltd
• F. Hoffmann-La Roche Ltd.
• Heptares Therapeutics Ltd.
• Novartis AG
• Omeros Corporation
• Rottapharm SpA
• Sellas Inc.

Drug Profiles

• ADX-71743
• ADX-88178
• bitopertin
• CR-5542 Series
• CR-5772 Series
• dipraglurant IR
• fluvoxamine maleate
• mavoglurant
• methoxycoronaridine
• OMS-527
• Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders
• Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders
• Small Molecules to Inhibit DAT and SERT for CNS Disorders
• zolpidem tartrate

For more information visit http://www.researchandmarkets.com/research/8qlfqw/obsessivecompulsi

[ Back To TMCnet.com's Homepage ]